---
title: "Morning Trend | GENSCRIPT BIO shows signs of bottom range fluctuation, with clear signals of main force wait-and-see"
description: "On November 20th, at the close, GENSCRIPT BIO (1548.HK) experienced price fluctuations throughout the day, maintaining a weak consolidation trend. After opening lower in the morning, both bulls and be"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/266691257.md"
published_at: "2025-11-21T01:00:00.000Z"
---

# Morning Trend | GENSCRIPT BIO shows signs of bottom range fluctuation, with clear signals of main force wait-and-see

> On November 20th, at the close, GENSCRIPT BIO (1548.HK) experienced price fluctuations throughout the day, maintaining a weak consolidation trend. After opening lower in the morning, both bulls and bears engaged in short-term tug-of-war. Although there was slight support, the overall trend was a continuous decline, with limited buying interest. The pharmaceutical and biotechnology sector showed weakened sentiment, with a scarcity of mainline hotspots in the sector. The news front lacked highlights, with no new drug applications, major agreements, orders, or new policy stimuli from the company. Market funds focused on high-growth technology and popular themes, while the pharmaceutical sector was in a cycle of institutional rotation and neglect. The MACD death cross structure remained unchanged, and the volume-price relationship was primarily characterized by shrinking volume and bottoming out. Intraday rebounds were mostly short-lived. The technical trend repeatedly tested important support zones, and the downward process lacked momentum, with no strong signals of stabilization seen in the bottom area. Right-side trading funds generally reduced risk exposure, and a wait-and-see sentiment dominated the market. If there are subsequent unusual movements in heavyweight pharmaceutical stocks or a significant increase in trading volume, the weak rebound window may be activated, but aggressive speculation is not recommended until the structure is repaired. Continuous attention should be paid to marginal events at the external and industry levels, such as the launch of important drugs in the sector, policy turning points, or favorable financing conditions. Once negative catalysts or policy strikes occur, the market's continued downside risk should be approached with high vigilance. The operational suggestion is to reduce risk positions and wait for right-side signals to appear

On November 20th, at the close, GENSCRIPT BIO (1548.HK) experienced price fluctuations throughout the day, maintaining a weak consolidation trend. After a lower opening in the morning, both bulls and bears engaged in short-term tug-of-war. Although there was slight support, the main trend was a continuous decline, with limited willingness to absorb buying. The pharmaceutical and biotechnology sector saw weakened sentiment, with a scarcity of mainline hotspots in the sector.

The news front lacked highlights, with the company having no new drug applications, major agreements, orders, or new policy stimuli. Market funds focused on high-growth technology and popular themes, while the pharmaceutical sector was in a cycle of institutional rotation and neglect. The MACD death cross structure remained unchanged, and the volume-price relationship was primarily characterized by reduced volume and bottoming out, with intraday rebounds mostly being short-lived.

The technical trend repeatedly tested important support zones, and the downward process lacked momentum, with no strong signals of stabilization seen in the bottom area. Right-side trading funds generally reduced risk exposure, and a wait-and-see sentiment dominated the market. If there are subsequent unusual movements in heavyweight pharmaceutical stocks or a significant increase in trading volume, a weak rebound window may be activated, but aggressive speculation is not recommended until the structure is repaired.

It is necessary to continuously monitor marginal events from external and industry levels, such as the launch of important drugs in the sector, policy turning points, or financing benefits. Once negative catalysts or policy strikes occur, there is a need for heightened vigilance regarding continued downward risks in the market. The operational suggestion is to reduce risk positions and wait for right-side signals to appear

### Related Stocks

- [01548.HK - GENSCRIPT BIO](https://longbridge.com/en/quote/01548.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 擁 100 萬資金買股好過買樓 關焯照看好銀行及地產股 15% 押注一隻 AI 股｜百萬倉 | 財經名家關焯照建議，若有 100 萬元，選擇買股票而非樓市。他看好本地地產股如恆地和長實，認為即使減派息，股息率仍可達 5 釐多。銀行股方面，推薦渣打，認為其上升空間優於滙豐。對於美股，關焯照看好光通訊和存儲晶片股，認為是科技巨頭投資的受益 | [Link](https://longbridge.com/en/news/276544696.md) |
| 發展黃金市場為今年重頭戲 許正宇：逾十銀行加入港金結算公司理事會 | 香港財經事務及庫務局局長許正宇表示，發展黃金市場是今年的重點，已與上海黃金交易所籤署合作協議，成立港金結算公司，預計年內啟動運作。超過 10 家銀行已確認加入理事會，目標是開發香港的黃金中央清算系統。此外，香港新股市場活躍，但對新股質素的關 | [Link](https://longbridge.com/en/news/276291952.md) |
| 風險偏好輪動正在加劇，但當前的支撐位至關重要 | 風險偏好輪動加劇，但支撐位現在至關重要 | [Link](https://longbridge.com/en/news/276350920.md) |
| 1750 億美元 “關税退款”！對美股是 “財政刺激”，對美債是 “增加債務”，對金銀是 “不確定性重來” | 1750 億美元潛在退款短期利好美股，零售消費股受益，但該裁決導致關税收入缺失，未來十年或為美債增加超 2 萬億美元負擔。特朗普表態將通過其他途徑重徵關税，政策不確定性加劇，黃金週五暴漲 2% 突破 5100 美元，白銀漲 8%，避險情緒升 | [Link](https://longbridge.com/en/news/276502057.md) |
| 別為美最高法推翻特朗普關税高興太早？華爾街預計市場反應或曇花一現 | 美國股債匯波動相對温和的一個重要原因是，預測市場此前已傾向於這一裁決結果，且特朗普隨後表示已有備用方案。雖然特朗普至少有五種替代的法律工具重新徵收關税，但無論採取何種方式，都將對長期美債的收益率構成上行壓力。 | [Link](https://longbridge.com/en/news/276487370.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.